Videos

INSIGHT tests if NSCLC super-responders with pathologic complete response can skip adjuvant durvalumab, reducing toxicity without sacrificing survival.

Dr. Monty Pal discusses the historical role of the International Metastatic Renal Cell Database Consortium (IMDC) risk criteria in guiding treatment decisions for advanced renal cell carcinoma (RCC) and explains why its influence has evolved in the current therapeutic landscape.

Dr. Monty Pal introduces the program by outlining the evolving treatment landscape for advanced renal cell carcinoma (RCC) and emphasizing the importance of translating clinical trial evidence and guideline recommendations into individualized patient care.

Heather J. Landau, MD, discusses results from a trial of the investigational CAR T-cell therapy NXC-201 in relapsed/refractory AL amyloidosis.

With 4 ROS1-directed TKIs now in the mix, community oncologists need a clear framework for sequencing and CNS considerations in this rare NSCLC subset.

Explore how genomics, comorbidities, and patient goals steer frontline CLL therapy, from fixed-duration venetoclax regimens to continuous BTK inhibitors.

Daniel Ermann, MD, discusses his approach to treatment sequencing in patients with chronic lymphocytic leukemia who aged 80 years and older.

Daniel Ermann, MD, discusses how real-world studies, such as his recent Medicare database analysis, are providing data on frontline BTK inhibitor (BTKi) therapy in populations of patients with chronic lymphocytic leukemia that are more representative of those oncologists would see in everyday practice.

Daniel Ermann, MD, discusses what real-world retrospective analyses have elucidated about BTK inhibitor (BTKi) therapy treatment selection in the frontline setting.

Daniel Ermann, MD, discusses a retrospective study he presented at the 2026 ASCO Annual Meeting that compared real-world Medicare database data for over 10,000 patients with chronic lymphocytic leukemia treated with frontline BTK inhibitor (BTKi) therapy: zanubrutinib (Brukinsa), acalabrutinib (Calquence), or ibrutinib (Imbruvica).

Daniel Ermann, MD, shares his expert insight on proactive management of patients with chronic lymphocytic leukemia receiving BTK inhibitor (BTKi) therapy to ensure optimal treatment, particularly in older patients.

Daniel Ermann, MD, discusses how clinical and real-world data drive his discussions with older CLL patients regarding frontline BTK inhibitor (BTKi) therapy.

Daniel Ermann, MD, discusses the significance of having both clinical trial and real-word data for frontline zanubrutinib in chronic lymphocytic leukemia.

Daniel Ermann, MD, highlights 6.5-year follow-up data for zanubrutinib from the phase 3 SEQUOIA trial, which compared the BTK inhibitor to chemoimmunotherapy in patients with chronic lymphocytic leukemia.

Daniel Ermann, MD, discusses treatment considerations with newly diagnosed older/elderly patients with chronic lymphocytic leukemia.

Daniel Ermann, MD, discusses what long-term clinical trial and real-world data have shown about the benefits and durability of continuous BTK inhibitor therapy in the frontline treatment of chronic lymphocytic leukemia.

SEQUOIA subgroup shows zanubrutinib sustains 64% PFS at 6 years in CLL patients ≥80, with low early discontinuations and manageable safety.

Ziftomenib combinations show promising frontline AML results, expanding trials with chemo and targeted partners; phase 3 aims to shift induction therapy standards worldwide.

KOMET-007 insights show ziftomenib’s manageable toxicity, low QTc risk, and easy oral dosing, supporting long-term AML therapy and maintenance.

Community oncology prepares for routine genetic testing, building workflows, training and follow-up to expand hereditary cancer risk care and reduce disparities.

ctDNA reveals hidden relapse risk as a clinician-scientist builds Northwell’s GI trials, uses AI for recruitment, and spotlights ASCO 2026 drugs.

Misako Nagasaka, MD, PhD, highlights progression-free survival data from the PALOMA-2 study among patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) receiving subcutaneous amivantamab plus lazertinib in the first-line setting. She compares these data with PFS data from the MARIPOSA trial, which evaluated intravenous amivantamab plus lazertinib in similar NSCLC populations.

Misako Nagasaka, MD, PhD, discusses results from the treatment-naïve populations in the PALOMA-2 study, which evaluated subcutaneous amivantamab plus lazertinib in patients with EGFR-mutated advanced or metastatic non–small cell lung cancer. She highlights study cohorts that explored the frontline combination using amivantamab every 2 weeks and every 4 weeks.

Ziftomenib plus 7+3 in newly diagnosed AML shows manageable safety and 90%+ deep responses with high MRD negativity and encouraging early survival in KOMET-007.

KOMET-007 data spotlight ziftomenib combos in newly diagnosed NPM1/KMT2A AML, detailing dosing, sequencing, and maintenance with 7+3 or aza/ven.

Young women with lung cancer face stigma, misdiagnosis, trial underrepresentation, and missed fertility support—clinical gaps that delay care and worsen long-term outcomes.

Andrew Spencer, MBBS, discusses how the inMMyCar trial is finding promise for in vivo CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Susan Bal, MD, discusses outcomes with arlo-cel, a GPRC5D-targeted CAR T product in relapsed/refractory multiple myeloma.

Johannes Schetelig, MD, MSc, discusses the importance of preventing life-threatening infections in light of research showing high nonrelapse mortality with PTCy.

Benjamin Herzberg, MD, highlights ASCO 2026's most exciting KRAS data, sequencing strategies, and emerging therapies for KRAS-mutant lung cancer.